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1. Introduction 
The metabolism of plasma chylomicrons and 
VLDL by LPL of the extrahepatic tissues results in 
the depletion of their core triacylglycerol and the loss 
of a proportion of their surface protein, phospholipid 
and cholesterol to the plasma HDL [1,2]. In the rat 
the resultant modified lipoproteins are avidly removed 
from the circulation by the liver and this process of 
removal is saturable and receptor-mediated [3,4]. 
The receptor-mediated binding and uptake of 
plasma LDL by fibroblasts i inhibited by the specific 
reaction of the guanido groups of the arginine residues 
of the lipoproteins with 1,2-cyclohexanedione [5 ]. 
Regeneration of the groups by treatment with 
hydroxylamine r -establishes binding and uptake. 
Here, we report hat cyclohexanedione tr atment 
similarly reversibly inhibits the uptake of partially- 
metabolized VLDL by the perfused rat liver. 
2. Materials and methods 
2.1.Animals 
Male Wistar albino rats were used and their source, 
maintenance diet and weight range were as specified 
in [4]. 
2.2. The production of  partially-metabolized VLDL 
Nascent VLDL, labelled in their triaeylglycerol 
fatty acids with [14C] oleic acid, were isolated from 
Abbreviations: VLDL, very low density lipoprotein; LDL, 
low density lipoprotein; HDL, high density lipoprotein; LPL, 
lipoprotein lipase 
rat liver perfusates as in [4]. Functionally hepatecto- 
mized and eviscerated rats [3] were each injected via 
the left jugular vein with 0.4-0.5 ml nascent VLDL 
(containing 13 mg triacylglycerol/ml). The animals 
were bled into tubes containing EDTA (final conc. 
1 mg/ml) by cannulation of the abdominal aorta 
40 rain after the injection. Partially-metabolized 
plasma VLDL were isolated as in [4] after the removal 
of erythrocytes by centrifugation. 
2.3.1,2-Cyclohexanedione modification of  partially- 
metabolized VLDL apoproteins 
Conditions for the modification of arginyl residues 
of proteins by 1,2-cyclohexanedione have been 
described [5,6]. Here, an aliquot (2 ml) of partially- 
metabolized VLDL containing ~2 mg protein/ml 
lipoprotein solution was mixed with 4 ml of a solu- 
tion of 1,2-cyclohexanedione (0.15 M) in borate 
buffer (0.2 M) (pH 8.1) and incubated at 35°C for 
2 h. The sample was then dialysed for 24 h against 
0.9% NaC1 solution and kept at 4°C until required. 
Modification of the arginyl residues by 1,2-cyclo- 
hexanedione is a reversible process. Native residues 
were regenerated by incubation of the dialysed 
1,2-cyclohexanedione-treated lipoprotein with an 
equal volume of hydroxylamine (1 M) in mannitol 
(0.3 M) (pH 7.0) at 37°C for either 7 or 16 h [5,6]. 
The lipoprotein solution was then exhaustively dia- 
lysed against 0.9% NaC1 solution. 
2.4. Liver perfusions for studies on the removal of  
partially-metabolized VLDL 
A recycling liver perfusion system [4] was used to 
study the removal of untreated, 1,2-cyclohexane- 
dione-treated and hydroxylamine-treated partially- 
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metabolized VLDL. In one group of experiments, the 
removal of untreated and 1,2-cyclohexanedione- 
treated lipoprotein was compared while in another 
the removal of untreated, 1,2-cyclohexanedione- 
treated and hydroxylamine-treated lipoprotein was 
examined. For each comparison, a single batch of 
partially-metabolized VLDL obtained from 4 per- 
fused livers was used and 18 functionally hepatec- 
tomized and eviscerated rats were injected for the 
preparation of partially-metabolized VLDL. 
After the addition of lipoprotein to the perfusion 
medium, the uptake of [14C]triacylglycerol-labelled 
lipoprotein by the perfused liver was monitored by 
following the removal of radioactivity at intervals up 
to 25 rain. At each time interval, 0.5 ml perfusion 
medium was removed and, after centrifugation to 
remove erythrocytes, 130/A supernatant was used for 
radioactivity measurements. 
2.5. Analytical methods 
Triacylglycerol, protein and radioactivity were 
measured as in [2]. For amino acid analysis, the 
delipidated apoprotein [71 was hydrolysed in HC1 
(6 M) for 24 h at 110°C [5] and the amino acid com- 
position determined by Dr J. B. C. Findlay of the 
Department of Biochemistry, University of Leeds, by 
analysis on an automated analyzer, Rank-Hilger 
Chromaspek J180. The peak areas were integrated by 
a Digico Micro 16 V computer. 
Electron microscopy was carried out by Mr D. 
Kershaw at the Department of Biochemistry, Univer- 
sity of Leeds. 
3. Results 
Changes in the lipid and protein composition of 
VLDL following their metabolism by the extrahepatic 
tissues of the rat have been determined in [2,8]. Here, 
the metabolism of injected VLDL in the hepatecto- 
mized rat resulted in the loss of some 60% of the 
injected triacylglycerol radioactivity by 40 rain. 
In [5] 1,2-cyclohexanedione reacted with exposed 
arginyl guanido groups of lipoproteins and quantita- 
tive regeneration of the arginyl residues was achieved 
by incubation of the 1,2-cyclohexanedione-treated 
lipoprotein with hydroxylamine. The data in table 1 
show that treatment with 1,2-cyclohexanedione 
under these conditions blocks some 50% of the arginyl 
residues of  partially-metabolized VLDL and that 
Table 1 
Amino acid composition of partially-metabolized rat VLDL 
apoprotein (no. residues/mol apoprotein) 
Amino Untreated 1,2-Cyclohexane- 1,2-Cyclohexane- 
acid VLDL dione-treated dione-treated and 
VL .DL  hydroxylamine- 
regenerated 
VLDL 
Asx 23 20 20 
Thr 22 25 22 
Ser 21 21 19 
Glx 38 30 30 
Pro 12 15 12 
Gly 19 21 19 
Ala 18 19 17 
Val 16 17 15 
Met 7 5 6 
lie 9 11 10 
Leu 30 28 27 
Tyr 7 6 6 
Phe 10 8 8 
Lys 17 15 17 
Arg 12 6 12 
VLDL was delipidated with ethanol:ether; 1 mg apoprotein 
was hydrolyzed with HCI (6 M) in the presence of 30 ul of 
mercaptoacetic a id at 110°C for 24 h in a sealed ampoule 
flushed with nitrogen. Amino acid residues are calculated 
assuming a total of 250 amino acid residues/tool fVLDL 
apoprotein [ 5 ] 
these are regenerated on incubation of the lipoprotein 
preparation with hydroxylamine. The percentage of 
arginyl residues modified is very similar to that in [5]. 
Negative-staining electron microscopy of the 
untreated and the 1,2-cyclohexanedione-treated lipo- 
proteins howed no difference in size or morphologi- 
cal appearance. The size of the particles ranged from 
150-1000 A, with some 85% of the particles being 
the range of 300-600 A. 
3.1. Removal of untreated, 1,2-cyclohexanedione- 
treated and hydroxylamine-regenerated, partially- 
metabolized VLDL by the perfused liver 
The triacylglycerol-rich lipoprotein fraction isolated 
from the plasma of the functionally hepatectomized 
and eviscerated rats contained partially-metabolized 
lipoproteins originating from the injected a4C-labelled 
VLDL and from endogenous chylomicrons and 
VLDL. The initial concentration of these lipoproteins 
(14C-labelled injected and endogenous) in this perfu- 
sion medium was 130-300/~g triacylglycerol/ml. 
This range was below that required to saturate the 
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receptor-mediated uptake mechanism (see [4]). 
Partially-metabolized VLDL are taken up by the 
perfused rat liver by a process that involves the 
uptake of the intact lipoprotein and the process can, 
therefore, be followed by monitoring the removal of 
the 14C-labelled triacylglycerol moiety of the per- 
fused lipoprotein [4]. Fig.1 compares the removal 
of the 14C-labelled triacylglycerol f untreated, 
1,2-cyclohexanedione-treated and hydroxylamine- 
regenerated, partially-metabolized VLDL by the per- 
fused liver• Over 25 min, some 60% of the untreated 
lipoprotein is removed (fig.1 a). Modification of the 
arginyl residues by 1,2-cyclohexanedione virtually 
abolishes this removal (fig.lb). When the arginyl resi- 
dues are regenerated byhydroxylamine treatment, 
removal again occurs and the extent of the removal 
increases with the time of exposure to hydroxylamine 
(fig. 1 c,d). 
4. Discussion 
The surface features of partially-metabolized chylo- 
microns and VLDL that are recognized by receptors 
in the liver of the rat have not been fully elucidated• 
The loss of surface apoprotein C from the parent lipo- 
proteins during triacylglycerol hydrolysis by LPL 
may be a prerequisite [9,10], as may be the loss of 
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Fig.l. Removal of partially-metabolized VLDL by tire perfused liver: (a,b) removal of untreated and 1,2-cyclohexanedione- 
treated, partially-metabolized VLDL, respectively; (c,d) removal of 1,2-cyclohexanedione-treated particles that had been incu- 
bated with hydroxylamine for 7 h and 16 h, respectively. (a,b) mean (+-SD) removal measured uring perfusions of 6 livers; (c,d) 
mean removal measured uring 2 liver perfusions. 
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surface phospholipid [ 11 ] and a decline in size of the 
lipoproteins [12]. However, a rise in the proportion 
of apoprotein E on the surface of the partially-metab- 
olized lipoprotein may well be of major importance. 
For example, apoprotein E addition promotes the 
hepatic uptake of chylomicrons [9,10] and HDLc, a 
l ipoprotein containing predominantly apoprotein E, 
competes with partially-metabolized chylomicrons 
for the same hepatic receptor-binding sites [ 13 ]. 
On the basis of the foregoing, it would be reason- 
able to assume that it is the reaction of 1,2-cyclo- 
hexanedione with the arginine residues of the apopro- 
rein E component of the partially-metabolized VLDL 
that is responsible for the inhibition of removal of 
these lipoproteins by the perfused liver here. How- 
ever, partially-metabolized VLDL contain a number 
of apoprotein species, notably apoprotein B, and 
1,2-cyclohexanedione can presumably react with the 
arginine residues of several of these. Moreover, 
[ 14,15] suggest hat the hepatic receptor can recog- 
nize apoprotein B as well as apoprotein E. It is there- 
fore certainly not possible to exlude the participation 
of other apoproteins in the removal process. 
The receptor-mediated binding and uptake of the 
plasma LDL by fibroblasts involves interaction with 
the apoprotein B component of the lipoprotein. 
However, this same receptor also binds, and with 
higher affinity, the apoprotein E of HDL c [16] and 
in addition binds partially-metabolized chylomicrons 
that contain both apoproteins B and E [17]. On the 
other hand, the liver receptor concerned with the 
uptake of partially-metabolized chylomicrons and 
VLDL has been shown under appropriate conditions 
to also bind both HDL c and LDL [18]. These obser- 
vations have led us to the suggestion that the hepatic 
and extra-hepatic high affinity l ipoprotein receptors 
resemble ach other closely and that both receptors 
recognize similar peptide sequences in the apopro- 
teins [ 18]. The present observation that the blockage 
of arginine residues with 1,2-cyclohexanedione pr - 
vents the uptake of partially-metabolized VLDL by 
rat liver, as it does the uptake of LDL and HDL c by 
fibroblasts [5], lends further support o this view. 
Tile report [ 19] showing that the Watanabe-heritable 
hyperlipidaemic rabbit lacks both the LDL receptor 
and the hepatic receptor for partially-metabolized 
chylomicrons, uggests indeed a common genetic ori- 
gin for the two receptors. 
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